Uganda Cancer Institute is a public, specialized, tertiary care medical facility owned by the Uganda Ministry of Health. The facility is located along Upper Mulago Hill Road, on Mulago Hill, in the Kawempe Division of Kampala, about 4.5 kilometres north of the central business district of the city.

There are 80 beds in Uganda Cancer Institute.

During the past decade, Uganda Cancer Institute conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Uganda Cancer Institute" #1 sponsor was "AIDS Malignancy Consortium" with 3 trials, followed by "Case Comprehensive Cancer Center" with 1 trials sponsored, "Fred Hutchinson Cancer Center" with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "Imara, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Uganda Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "The Emmes Company, LLC" with 3 trials as a collaborator, "University of Arkansas" with 3 trials as a collaborator, "University of California, Los Angeles" with 3 trials as a collaborator and "AIDS and Cancer Specimen Resource" with 2 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Uganda Cancer Institute" are "Skin Kaposi Sarcoma" (2 trials), "AIDS-Related Human Papillomavirus Infection" (1 trials), "Anatomic Stage IIB Breast Cancer AJCC v8" (1 trials), "Anatomic Stage III Breast Cancer AJCC v8" (1 trials) and "Anatomic Stage IIIA Breast Cancer AJCC v8" (1 trials). Many other conditions were trialed in "Uganda Cancer Institute" in a lesser frequency.

Most popular intervention types in "Uganda Cancer Institute" are "Drug" (6 trials), "Other" (3 trials), "Biological" (2 trials), "Behavioral" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (3 trials), "Biospecimen Collection" (1 trials), "Capecitabine" (1 trials), "Cyclophosphamide" (1 trials) and "Endocrine Therapy of Physician's Choice" (1 trials). Other intervention names were less common.

The vast majority of trials in "Uganda Cancer Institute" are 5 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Uganda Cancer Institute". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Uganda Cancer Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Uganda Cancer Institute, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".